(Información remitida por la empresa firmante)
The information in the press release is information that Orexo is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on October 11, 2023, at 8 am CET.[1] American Society of Addiction Medicine: J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91. doi: 10.1097/ADM.0000000000000633.
[2]Lofwall MR et al, JAMA Intern Med. 2018;178(6):764-773. doi:10.1001/jamainternmed.2018.1052
[3]Haight BR et al, Lancet. 2019:393:778-790. doi:10.1016/S0140-6736(18)32259-1
[4] Carroll KM et al. Am J Psychiatry 2017;174:738-747. doi:10.1176/appi.ajp.2016.16070792
[5] Galanter M et al, Am J Addictions 2020;29:271-278
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/orexo-announces-data-from-the-modia-study-evaluating-impact-on-use-of-illicit-opioids-301953229.html